Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growth (NYSE:GKOS)
Glaukos(US:GKOS) Seeking Alpha·2025-10-30 12:07To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...